| Author (Corporate) | European Medicines Agency |
|---|---|
| Series Title | Press Release |
| Series Details | EMA/CHMP/401327/2011 (27.5.11) |
| Publication Date | 27/05/2011 |
| Content Type | News |
|
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) was informed, in May 2011, that a specific batch of the Japanese encephalitis vaccine, Ixiaro (batch JEV09L37), manufactured by Intercell AG, may be less potent than expected and may not induce a full protective immune response in vaccinees. Therefore, as a precautionary measure, Intercell AG recalled batch JEV09L37 of Ixiaro throughout the European Union (EU). It was recommended that by the Committee for Medicinal Products for Human Use (CHMP) that individuals who had already received one or two doses of Ixiaro from this batch and who were planning to travel soon to regions of exposure to Japanese encephalitis, should consider revaccination with a different batch. This disease is most prevalent in Southeast Asia and the Far East. |
|
| Source Link | Link to Main Source http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2011/05/news_detail_001263.jsp&mid=WC0b01ac058004d5c1&murl=menus/news_and_events/news_and_events.jsp |
| Related Links |
|
| Countries / Regions | Europe |
